Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.
The company released trial data on its lead therapy, Elahere, designed to treat ovarian cancer.
The biotech company's first-quarter report had plenty of good news.
IMGN earnings call for the period ending June 30, 2022.
IMGN earnings call for the period ending March 31, 2022.
IMGN earnings call for the period ending December 31, 2021.
IMGN earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.